共 50 条
The multiple facets of ovarian high grade serous carcinoma: A review on morphological, immunohistochemical and molecular features
被引:0
作者:
Santoro, Angela
[1
,2
]
Angelico, Giuseppe
[3
]
Travaglino, Antonio
[4
]
Inzani, Frediano
[5
,6
]
Spadola, Saveria
[3
]
Pettinato, Angela
[7
]
Mazzucchelli, Manuel
[8
]
Bragantini, Emma
[9
]
Maccio, Livia
[9
]
Zannoni, Gian Franco
[1
,2
]
机构:
[1] Univ Cattolica Sacro Cuore, Pathol Inst, I-00168 Rome, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Dept Woman & Childs Hlth & Publ Hlth Sci, Pathol Unit, I-00168 Rome, Italy
[3] Kore Univ Enna, Dept Med & Surg, I-94100 Enna, Italy
[4] Univ Insubria, Dept Med & Technol Innovat, Pathol Unit, Varese, Italy
[5] Univ Pavia, Dept Mol Med, Anat Pathol Unit, I-27100 Pavia, Italy
[6] Fdn IRCCS San Matteo Hosp, I-27100 Pavia, Italy
[7] AOE Cannizzaro, Dept Pathol Anat, Via Messina,829, I-95126 Catania, Italy
[8] Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Anat Pathol, Catania, Italy
[9] Santa Chiara Hosp, Unit Surg Pathol, APSS, Trento, Italy
关键词:
Ovarian cancer;
P53;
BRCA;
Homologous recombination repair;
TCGA;
TILs;
PLATINUM-RESISTANT OVARIAN;
FOLATE RECEPTOR-ALPHA;
ANTITUMOR-ACTIVITY;
DNA-REPAIR;
PHASE-II;
T-CELLS;
CANCER;
EXPRESSION;
MUTATIONS;
ANTIBODY;
D O I:
10.1016/j.critrevonc.2024.104603
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
High-grade serous ovarian carcinoma (HGSOC) is the most aggressive subtype of epithelial ovarian cancer and a leading cause of mortality among gynecologic malignancies. This review aims to comprehensively analyze the morphological, immunohistochemical, and molecular features of HGSOC, highlighting its pathogenesis and identifying biomarkers with diagnostic, prognostic, and therapeutic significance. Special emphasis is placed on the role of tumor microenvironment (TME) and genomic instability in shaping the tumor's behavior and therapeutic vulnerabilities. Key advancements, such as the identification of TP53 and BRCA mutations, the classification of homologous recombination repair (HRR) deficiencies, and the clinical implications of biomarkers like folate receptor alpha (FR alpha) and PD-L1 are discussed. These findings reveal actionable insights into targeted therapies, including immune checkpoint inhibitors and PARP inhibitors, which hold promise for improving outcomes in HGSOC. This synthesis of knowledge aims to bridge gaps in understanding HGSOC's multifaceted biology, enhance clinical decision-making, and foster the development of precision therapies.
引用
收藏
页数:10
相关论文
共 50 条